Moreover, the presence of BRAF status, which occurs in approximately 10% of colorectal cancer, has been considered a predictive marker in the survival of patients with metastatic colorectal cancer because the mutation status correlates with lower therapeutic response to chemotherapy with or without target agents [35]. Here, BRAF is linked to metastatic colorectal cancer.